President Donald Trump will sign three executive orders on lowering prescription drug prices, White House Chief of Staff Mark Meadows said.

Zolgensma’s successful market uptake by payers may hold lessons for other manufacturers of costly gene therapies.

Among many of the insights provided in the IQVIA Institute for Human Data Science report “Global Medicine Spending and Usage Trends: Outlook to 2024,” global medicine spending is projected to increase from 2 percent to 5 percent annually through 2024 on a net basis, compared to 4.2 percent in the past five years.

One of the arguments biopharma companies make for the high cost of new drugs is the expense of drug development. A new study published in JAMA Network, “Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the U.S., 2007-2018,” provides some concrete data to the argument.

With impeachment behind us and the elections looming, both parties are focused on healthcare, the policy topic of greatest concern to voters. More specifically, they are focused on lowering the cost of prescription drugs.

As the 2020 presidential election looms, debate about the price of prescription drugs and healthcare will intensify; healthcare communication leaders share their thoughts on how their pharma clients can be a constructive part of the conversations.

Even as lawmakers debate and malign proposed plans to lower the costs of prescription drugs in the United States, since the start of 2020, prices increased on more than 600 prescription drugs by an average of 5.2 percent.

CVS Health Corp.’s pharmacy benefit management (PBM) unit is launching a new program under which employers and insurers will be able to offer diabetes drugs, including insulin, at no out-of-pocket costs to their members.

The Federal Trade Commission filed a complaint in federal court against Vyera Pharmaceuticals, the company formerly known as Turing Pharmaceuticals that Martin Shkreli founded, alleging an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim.

Sickle cell disease drugs made by Novartis and Global Blood Therapeutics (GBT) may not be cost effective at current prices, a draft report published on Friday suggested, widening the debate over U.S. healthcare affordability.